Polypharmacy, potentially inappropriate medications, and chemotherapy-related adverse events among older adults with cancer.Ronald J. Maggiore, Arti Hurria, Vani Katheria et al.|Journal of Clinical Oncology|2011Cited by 11
Measures of polypharmacy and chemotherapy toxicity in older adults with cancer.Ronald J. Maggiore, Arti Hurria, Tao Feng et al.|Journal of Clinical Oncology|2013Cited by 7
Predictors of primary dose reduction (PDR) among patients (pts) age 65 and older receiving adjuvant chemotherapy (chemo).Heidi D. Klepin, Arti Hurria, Ajeet Gajra et al.|Journal of Clinical Oncology|2011Cited by 2
Primary dose reduction (PDR) of chemotherapy (chemo) in patients (Pts) older than age 65 with advanced cancer (Ca) and toxicity outcomes.Ajeet Gajra, Arti Hurria, Molly Hardt et al.|Journal of Clinical Oncology|2011Cited by 1
P5-19-05: Age-Related Changes in the Pharmacokinetics (pK), Response, and Toxicity of Weekly nab-Paclitaxel in Patients with Metastatic Breast Cancer (MBC).Arti Hurria, George Somlo, Timothy W. Synold et al.|Cancer Research|2011Cited by 0